QLGN QUALIGEN THERAPEUTICS INC Delisting Actions 8-K Filing 2024 - Nasdaq Compliance Qualigen Therapeutics received a notice from Nasdaq for not meeting the requirement of having three independent directors on its Audit Committee after a board member's resignation, but has until April 2025 to comply without immediate impact on its stock listing.Get access to all SEC 8-K filings of the QUALIGEN THERAPEUTICS INC